What second-line treatment would you offer a patient with BRAF V600E–mutant mCRC after progression on EC + FOLFIRI?

Do you continue EC with a different chemotherapy backbone or drop targeted therapy altogether? Kopetz et al. DOI:10.1200/JCO.2026.44.17_suppl.LBA3503